Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2013 Jan 18;33(1):27-45. doi: 10.3265/Nefrologia.pre2012.Nov.11781. English, Spanish.

2.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9. English, Spanish.

3.

A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.

Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC.

Neth J Med. 2012 Apr;70(3):121-9. Review.

4.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
5.

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.

Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J.

Pediatr Nephrol. 2012 Dec;27(12):2323-6. doi: 10.1007/s00467-012-2276-8. Epub 2012 Aug 14.

6.

Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

Wong EK, Goodship TH, Kavanagh D.

Mol Immunol. 2013 Dec 15;56(3):199-212. doi: 10.1016/j.molimm.2013.05.224. Epub 2013 Jun 28. Review.

7.

Atypical haemolytic uraemic syndrome.

Kavanagh D, Goodship TH, Richards A.

Br Med Bull. 2006;77-78:5-22. Epub 2006 Sep 11. Review.

PMID:
16968692
8.
9.

Haemolytic uraemic syndrome.

Karpman D, Loos S, Tati R, Arvidsson I.

J Intern Med. 2017 Feb;281(2):123-148. doi: 10.1111/joim.12546. Epub 2016 Oct 10. Review.

PMID:
27723152
10.

Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.

Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.

Pediatrics. 2014 Jun;133(6):e1764-8. doi: 10.1542/peds.2013-1594.

11.

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.

Taylor CM, Machin S, Wigmore SJ, Goodship TH; working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society.

Br J Haematol. 2010 Jan;148(1):37-47. doi: 10.1111/j.1365-2141.2009.07916.x. Epub 2009 Oct 11.

PMID:
19821824
12.

[Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].

Vaisbich MH, Henriques Ldos S, Watanabe A, Pereira LM, Metran CC, Malheiros DA, Modanez F, Silva JD, Vieira S, Macedo AC, Massarope B, Furusawa EA, Schvartsman BG.

J Bras Nefrol. 2013 Jul-Sep;35(3):237-41. doi: 10.5935/0101-2800.20130037. Review. Portuguese.

13.

Eculizumab in secondary atypical haemolytic uraemic syndrome.

Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M.

Nephrol Dial Transplant. 2017 Mar 1;32(3):466-474. doi: 10.1093/ndt/gfw453.

14.

Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.

Okumi M, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776. Review.

PMID:
26988663
15.

Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.

Verhave JC, Wetzels JF, van de Kar NC.

Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv131-41. doi: 10.1093/ndt/gfu235. Review.

PMID:
25165180
16.

Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.

Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W.

Pediatrics. 2014 Jun;133(6):e1759-63. doi: 10.1542/peds.2013-1787.

17.

Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.

Ikeda T, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:35-40. doi: 10.1111/nep.12768.

PMID:
26970541
18.

Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.

Fakhouri F, Frémeaux-Bacchi V, Loirat C.

Eur J Intern Med. 2013 Sep;24(6):492-5. doi: 10.1016/j.ejim.2013.05.008. Epub 2013 Jun 5. Review.

PMID:
23756030
19.

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.

Nester CM, Brophy PD.

Curr Opin Pediatr. 2013 Apr;25(2):225-31. doi: 10.1097/MOP.0b013e32835df4a3. Review.

PMID:
23486421
20.

Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.

Békássy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-Bacchi V, Karpman D.

Nephrol Dial Transplant. 2013 Nov;28(11):2899-907. doi: 10.1093/ndt/gft340. Epub 2013 Sep 5.

PMID:
24009284

Supplemental Content

Support Center